1-3 of 3
Takeshi Yoshida
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer

Free
Satomi Watanabe, Takeshi Yoshida, Hisato Kawakami, Naoki Takegawa, Junko Tanizaki, Hidetoshi Hayashi, Masayuki Takeda, Kimio Yonesaka, Junji Tsurutani, Kazuhiko Nakagawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (11): 2563–2571.
https://doi.org/10.1158/1535-7163.MCT-17-0351
Published: 01 November 2017
View article titled, T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer
Open the PDF for T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer in another window
Journal Articles

Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition

Free
Wataru Okamoto, Isamu Okamoto, Takeshi Yoshida, Kunio Okamoto, Ken Takezawa, Erina Hatashita, Yuki Yamada, Kiyoko Kuwata, Tokuzo Arao, Kazuyoshi Yanagihara, Masahiro Fukuoka, Kazuto Nishio, Kazuhiko Nakagawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (5): 1188–1197.
https://doi.org/10.1158/1535-7163.MCT-10-0002
Published: 09 May 2010
View article titled, Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition
Open the PDF for Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition in another window
Includes: Supplementary data
Journal Articles

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase

Free
Takafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, Junji Uchida, Tsutomu Iwasa, Takeshi Yoshida, Erina Hatashita, Yuki Yamada, Taroh Satoh, Kenji Tamura, Masahiro Fukuoka, Kazuhiko Nakagawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 599–606.
https://doi.org/10.1158/1535-7163.MCT-07-0567
Published: 17 March 2008
View article titled, Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
Open the PDF for Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase in another window